At a glance
CANSINO BIOLOGICS INC. (CanSino) is a biotechnology company dedicated to the R&D,
manufacturing and commercialization of vaccine products for human use. The company was founded
in Tianjin Economic and Technological Development Area (TEDA) in 2009. The founding party of
CanSino consist of scientists and managers who have previously held senior management and
technical positions in some of the world¡¯s leading pharmaceutical companies. The management team
has a proven track record of success in new drug discovery, development and commercialization.
In addition, CanSino¡¯s scientific advisory board is comprised of internationally recognized senior
executives and leading members of academia who provide unique and complementary insights to
guide the company¡¯s growth.
CanSino¡¯s mission is to develop high value and high quality vaccines for China and other emerging
countries at an affordable cost. Equipped with cutting edge scientific know-how and technology,
CanSino¡¯s goal is to lead and foster the Chinese vaccine industry into a major contributor to global
public health. In order to minimize the gap in quality and technique between the Chinese vaccine
industry and world vaccine leaders, expertise such as that possessed by CanSino is invaluable.
Currently, CanSino is working on products that are in high demand but are lacking in supply or quality,
such as quadrivalence (ACYW135) Meningococcal conjugate vaccine, Pneumococcal polysaccharide
and conjugate vaccines, as well as a DTcP based combo and other products. Simultaneously, CanSino
is also devoted to new vaccine development, such as a recombinant adenovirus vector based
tuberculosis vaccine and a recombinant protein based pneumococcal vaccine.
¡°Vaccination is an essential part of effective disease control and prevention. Our ultimate goal is to
make top quality vaccines accessible to people all over the world.¡±
- Xuefeng Yu PhD.
Chairman and CEO of CanSino